Relay Therapeutics CFO sells 17,717 shares at $19.74

Rhea-AI Filing Summary

Relay Therapeutics, Inc. (RLAY) reported that its Chief Financial Officer, Thomas Catinazzo, sold 17,717 shares of common stock on August 14, 2026 in an open-market transaction at a weighted average price of $19.74 per share, under a previously adopted Rule 10b5-1 trading plan. After this sale, he directly holds 140,568 shares of Relay Therapeutics common stock, which include 6,538 shares underlying restricted stock units.

Insider Trade Summary 10b5-1

Net Seller: 17,717 shares

Net Sell 1 txn

Insider Catinazzo Thomas

Role Chief Financial Officer

Sold 17,717 shs ($350K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	17,717	$19.74	$350K

Holdings After Transaction: Common Stock — 140,568 shares (Direct)

Footnotes (3)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
2. F2. This transaction was executed in multiple trades at prices ranging from $19.51 to $19.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
3. F3. Includes 6,538 shares underlying restricted stock units.

Key Figures

Shares sold: 17,717 shares Weighted average sale price: $19.74 per share Post-transaction holdings: 140,568 shares +3 more

6 metrics

Shares sold 17,717 shares Common stock sold by CFO Thomas Catinazzo on August 14, 2026

Weighted average sale price $19.74 per share Average price for the 17,717 shares sold on August 14, 2026

Post-transaction holdings 140,568 shares Shares of Relay Therapeutics common stock directly held after the sale

RSUs included in holdings 6,538 shares Shares underlying restricted stock units included in post-sale holdings

10b5-1 plan adoption date October 30, 2025 Date CFO’s Rule 10b5-1 trading plan used for this sale was adopted

Trade price range $19.51 to $19.96 per share Range of prices at which the 17,717 shares were sold in multiple trades

Key Terms

Rule 10b5-1 trading plan, restricted stock units, weighted average sale price, open market or private transaction

4 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

restricted stock units financial

"Includes 6,538 shares underlying restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price"

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Relay Therapeutics (RLAY) disclose for CFO Thomas Catinazzo?

Relay Therapeutics disclosed that CFO Thomas Catinazzo sold 17,717 shares of common stock on August 14, 2026. The sale was executed in the open market under a Rule 10b5-1 trading plan at a weighted average price of $19.74 per share.

At what price did the RLAY CFO sell his shares on August 14, 2026?

The CFO’s sale used a weighted average price of $19.74 per share for 17,717 shares. Individual trades occurred in multiple transactions at prices ranging from $19.51 to $19.96, as disclosed in the footnotes to the Form 4.

How many Relay Therapeutics (RLAY) shares does the CFO hold after the reported sale?

After the sale, CFO Thomas Catinazzo directly holds 140,568 shares of Relay Therapeutics common stock. This amount includes 6,538 shares underlying restricted stock units, which are equity awards that typically vest over time under company compensation plans.

Was the RLAY CFO’s August 14, 2026 sale made under a Rule 10b5-1 plan?

Yes. The company reported that the August 14, 2026 sale was effected under a Rule 10b5-1 trading plan. The footnote states the plan was adopted on October 30, 2025, indicating the transactions were pre-arranged rather than opportunistic.

What is the trade size of the Relay Therapeutics (RLAY) CFO’s Form 4 sale?

The disclosed transaction involved the sale of 17,717 shares of Relay Therapeutics common stock. These shares were sold in multiple trades within a $19.51–$19.96 price range, reported as a weighted average price of $19.74 on the Form 4.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/18/2026 - 04:17 PM Accepted by SEC EDGAR 08/18/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Catinazzo Thomas

(Last) (First) (Middle)

C/O RELAY THERAPEUTICS, INC.

60 HAMPSHIRE STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Relay Therapeutics, Inc. [ RLAY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/14/2026		S(1)		17,717	D	$19.74(2)	140,568(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.

2. This transaction was executed in multiple trades at prices ranging from $19.51 to $19.96. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

3. Includes 6,538 shares underlying restricted stock units.

	/s/ Soo-Yeun Lim, as Attorney-in-Fact	08/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)